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Excluding PTV from lung volume may
better predict radiation pneumonitis for
intensity modulated radiation therapy in
lung cancer patients
Yinnan Meng1,2, Haihua Yang1,2* , Wei Wang1,2, Xingni Tang1,2, Caiping Jiang1,2, Yichao Shen1,2 and Wei Luo3*

Abstract
Background: Lung dose-volume histogram (DVH) in radiotherapy could be calculated from multiple normal lung
definitions. The lung dosimetric parameters generated from various approaches are significantly different. However,
limited evidence shows which definition should be used to more accurately predict radiation pneumonitis (RP). We
aimed to compare the RP prediction accuracy of dosimetric parameters from three lung volume methods in lung
cancer patients treated with Intensity-Modulated Radiation Therapy (IMRT).
Methods: We retrospectively reviewed 183 consecutive lung cancer patients treated with IMRT from January 2014 to
October 2017. The normal lungs were defined by total bilateral lung volume (Total Lung), excluding PTV (Lung-PTV) or
PGTV (Lung-PGTV). V5, V20, and mean lung dose (MLD) have been extracted from three definitions. The primary endpoint
was acute grade 2 or higher RP (RP2). Correlation between RP2 and dose parameters were analyzed by logistic regression.
We evaluated prediction performance using area under the receiver operating characteristic curve (AUC) and normal
tissue complication probability (NTCP) model.
Results: Twenty-six patients (14.2%) developed acute RP2 after IMRT treatment. Significant dosimetric differences were
found between any 2-paired lung volumes (Ps < 0.001). To limit RP2 incidence less than 20%, the cutoff MLDs were 12.
5 Gy, 14.2 Gy, and 15.0 Gy, respectively, for Lung-PTV, Lung-PGTV, and Total Lung methods. There were 54% (13%
vs. 20%) and 45% (20% vs. 29%) RP2 probability variances detected at each MLD cutoff points from Lung-PTV and
Lung-PGTV definitions. The best RP prediction performance was found in MLD from Lung-PTV method (AUC = 0.647),
which is significantly better (P = 0.006) than the MLD from Lung-PGTV method (AUC = 0.609).
Conclusion: There are significant differences in acute RP2 rate prediction using dosimetric parameters from various
normal lung definitions. Excluding PTV from total lung volume may be more accurate and promising to predict acute
symptomatic radiation pneumonitis in IMRT treated lung cancer patients.
Keywords: Lung volume, Radiation pneumonitis (RP), Intensity modulated radiation therapy (IMRT), Lung cancer
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Background
Radiation therapy (RT) plays an important role in lung
cancer treatment, but grade 2 or higher radiation pneumonitis (RP2) remains an essential dose-limiting obstacle and
can significantly reduce the therapeutic ratio and patient’s
quality of life [1–3]. Lung volume receiving more than
20 Gy (V20) and mean lung dose (MLD) generated
from dose-volume histograms (DVHs) are the most common traditional dosimetric parameters in clinical treatment
planning evaluation [4–6]. Some retrospective analyses
have also correlated radiation pneumonitis with low-dose
parameters, such as the V5 [7, 8].
For the past decade, three-dimensional conformal external beam radiation therapy (3D-CRT) with concurrent
chemotherapy was commonly to treat unresectable local
advanced lung cancer, but there has been increasing use
of intensity-modulated radiation therapy (IMRT) [9–11].
In the 2018 NCCN guideline in NSCLC version 4 updates,
according to a secondary analysis of RTOG 0617, the
IMRT is currently recommended as a preferred RT technique over 3DCRT [12]. IMRT group was associated with
a decrease of grade ≥ 3 RP incidence from 7.9 to 3.5% with
similar survivals and tumor control outcomes, despite
larger tumors, higher V5 s, similar V20 s, and MLDs [13].
The available dose constraints are generally from previous
3D-CRT studies, due to the more unconstrained beam
arrangements and nonstandard dose distribution, they
may have lower radiation pneumonitis prediction value
for the IMRT [5, 6]. More precise dose constraints for the
IMRT technique need to be further developed instead of
using the conventional constraints from 3D-CRT.
Moreover, the normal lung volume definitions for DVH
calculation are found inconsistent in the previous studies,
which could have a significant impact on the variance of
dose parameters and the evaluation of clinical treatment
decision [14, 15]. In RTOG 0617 the lung volume was
defined as the bilateral lung volume excluding the CTV
(Lung-CTV). It was more commonly defined as the
bilateral lung excluding the planning target volume
(Lung-PTV) [5, 16, 17] or excluding the gross tumor
volume (Lung-GTV) [1, 3, 4]. Currently, both RTOG and
ESTRO-ACROP guidelines recommend using Lung-GTV
delineation instead of Lung-PTV to standardize lung
volume definition among different institutions [18, 19].
But limited clinical evidence shows which normal lung
definition is better for symptomatic radiation pneumonitis
prediction, especially using IMRT or VMAT which has a
non-standard dose distribution outside treatment target.
In the IMRT era for lung cancer patients, we hypothesized that a significant dosimetric parameters variation
could still be found among different total lung definitions, and a specific normal lung defined method could
be superior to the others in RP2 prediction. In our study,
we compared the numeric dose difference and the acute
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RP2 prediction performance among dose parameters
from three normal lung definitions.

Methods
Patients

This study was approved by the Institutional Review
Board, which waived written informed consent because
of the retrospective design. We retrospectively reviewed
183 lung cancer patients received IMRT at our institution
between January 2014 and September 2017. The inclusion
criteria were the first time receiving thorax RT, having
received only IMRT technique with RT alone or combine
with either surgery or chemotherapy, prescription
dose PGTV≥50 Gy in 2.00–2.20 Gy and PTV ≥ 45 Gy
in 1.80 Gy daily fractions using 6 MV photons, having
available dosimetric data, and having follow-up records
for at least 3 months.
Image-guided RT including orthogonal megavoltage
electronic portal imaging or kilovoltage cone beam computed tomography (CBCT) was used to reduce the interfraction geometric displacement from the daily setup error and
the anatomic change. The patients with a mid-treatment
computed tomography (CT) scan and a replanning adaptive
radiotherapy were not included in this study. Dosimetric
factors evaluated were V5, V20, and MLD from three normal lung definitions. Clinical factors analyzed including age,
gender, smoking status, tumor histology and stage, receipt of
chemotherapy or surgery, target prescription and volume.
Treatment planning

Treatment planning CT scans were performed with patients
in the treatment position, immobilized in the supine
position with their arms above their head. Scans should
include the entire thorax for at least 5 mm slice thickness.
The pretreatment positron emission tomography (PET)/
CT may be used in staging and tumor volume delineation.
The 4D CT or 4D PET/CT scan has not been applied to
the patients receiving IMRT treatment in our department.
Gross tumor volume (GTV), defined as visible primary
tumor and positive metastatic lymphadenopathy treatment planning CT or pretreatment PET scan. Clinical
target volume (CTV) was defined as GTV with a 0.5 cm to
1 cm margin combined with positive lymph node involved
region to cover the microscopic tumor extension. The
GTV margin was approximate 6 mm for squamous cell or
8 mm for other types. The tumor and target volumes were
contoured by treating physicians under the supervision of
a senior radiation oncologist. The planning gross tumor
volume (PGTV) and planning target volume (PTV) was
defined as the GTV and CTV with a 5 mm uniform expansion to account for the setup margin.
RT planning was done using Pinnacle treatment planning system (Philips Medical Systems, Andover, MA)
with Collapsed Cone Convolution algorithm or Eclipse
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software (Varian medical systems, Palo Alto, CA) with
Analytical Anisotropic Algorithm. The radiation dose
distribution was calculated using lung heterogeneity
corrections.
Lung volume definition and lung DVH

Lung was contoured in CT datasets using pulmonary
windows via threshold auto-segmentation followed by
manual edits. All inflated, collapsed, fibrotic, and emphysematous lung tissues were contoured with the inclusion
of small vessels in the lung parenchyma. Great vessels,
trachea, and proximal bronchial tree were excluded.
Three sets of normal lung DVHs were generated by
using the total bilateral lung volume (Total Lung), with
the exclusion of targets of planning GTV from bilateral
lung (Lung-PGTV) and PTV (Lung-PTV) (Fig. 1). Target exclusion was performed by overlapping rules (i.e.,
only the intrapulmonary parts of targets were subtracted). From each bilateral lung DVH, three dosimetric
factors were extracted: V5, V20, and MLD. The V5/20
was defined as the percentage of total normal lung volume receiving equal to or greater than 5/20 Gy of
radiation.
Evaluation of radiation pneumonitis

RP was diagnosed and graded based on clinical and
radiographic presentations, according to the National
Cancer Institute’s Common Terminology Criteria for
Adverse Events, version 4.03 [20]. In brief, diagnosis of RP
required the presence of radiographic pneumonitis not
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attributable to other causes such as infection or tumor
recurrence.
Grade 1 pneumonitis was radiographic RP with no or
minimal symptoms that did not require medical intervention; grade 2 was symptomatic but did not interfere
with daily activities; grade 3 was symptomatic and interfered with daily activities or required administration of
oxygen to the patient; grade 4 required assisted ventilation
for the patient; and grade 5 pneumonitis was fatal. A
symptomatic RP event for analysis was defined as RP2.
The endpoint for this analysis was acute RP2 happened
≤3 months.
Lyman NTCP model parameters

We built the MLD-RP2 association curve using the Lyman
model. The dosimetric and RP2 data from 183 patients
were used to fit the NTCP model. When volume-effect parameter n = 1, the NTCP equation reduces to an expression
representing the mean lung dose. We use the log-likelihood
function to get best-fit parameters m and TD50 [21].
Statistical analysis

For description, we used the mean and 95% confidential
interval (CI) for normal distribution continuous variables,
median and range for non-normal continuous variables;
categorical variables are reported as count and percentage.
Univariate logistic regression analysis was performed to
evaluate the correlation between clinical and dosimetric
factors with the onset of acute symptomatic RP. Dosimetric factors from the different methods DVH calculation

Fig. 1 Contouring examples of targets and three normal lung definitions. a GTV = Gross Tumor Volume; PGTV = Planning Gross Tumor Volume;
CTV = Clinical Target Volume; PTV = Planning Target Volume. b Directly using total bilateral lung volume definition. c Excluding PGTV from total
bilateral lung volume definition. d Excluding PTV from total bilateral lung volume definition
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were compared using repeated analysis of variance test
(ANOVA). Dose difference evaluation is presented as
mean and 95% CI. The difference of dosimetric factors
between acute RP2 and non-RP2 patients were compared with the Mann-Whitney U test (Equivalent with

Wilcoxon rank-sum test). The area under the curve (AUC)
of receiver operating characteristic (ROC) curves were
calculated to quantify the ability of the various V5, V20,
and MLD. The increase in the AUC was evaluated for
significance using the test proposed by DeLong et al. [22].

Table 1 Baseline and clinical characteristics of patients and their correlation with grade ≥ 2 acute radiation pneumonitis
No. of Patients
(N = 183) (%)

No. of Grade ≥ 2 RP
(N = 26) (%)

Odds Ratio

≤ 63 (Median)

98 (53.6)

13(50.0)

Reference

> 63 (Median)

84(45.9)

13(50.0)

1.21

Male

162(88.5)

20(76.9)

Reference

Female

21(11.5)

6(23.1)

2.84

Never

42(23.0)

7(26.9)

Reference

Current

77(42.1)

12(46.2)

0.92

0.33–2.56

0.878

Former

64(35.0)

7 (26.9)

0.61

0.20–1.90

0.397

Squamous

112(61.7)

19 (73.1)

Reference

Adenocarcinoma

30(16.4)

3(11.5)

0.54

0.15–1.98

0.355

Small Cell

35(19.7)

3(11.5)

0.46

0.13–1.65

0.234

Others

6(2.2)

1(3.8)

0.98

0.11–8.86

0.985

I/II

14(7.7)

0(0)

0.00

0.999

III

115(62.8)

20 (76.9)

Reference

0.578

IV

54(29.5)

6 (23.1)

0.59

Characteristics

95% CI

P Value*

0.53–2.78

0.651

0.99–8.17

0.053

Age

Gender

Smoking
0.644

Pathology
0.570

Stage

0.22–1.58

0.295

0.58–34.89

0.149

0.35–2.51

0.901

0.44–2.32

0.976

0.20–1.15

0.101

0.63–3.38

0.373

0.26–3.46

0.935

Chemo
No

25(13.7)

1(3.8)

Reference

Yes

158(86.3)

25(96.2)

4.51

No

139(76)

20(76.9)

Reference

Yes

44(24)

6(23.1)

0.94

≤ 135.1 (Median)

92(50)

13(50)

Reference

> 135.1 (Median)

91(50)

13(50)

1.0

≤ 543.6 (Median)

92(50)

17(65)

Reference

> 543.6 (Median)

91(50)

9(35)

0.48

Surgery

PGTV Volume

PTV Volume

PGTV prescription
≤ 54 (Median)

113(62)

14(54)

Reference

> 54 (Median)

70(38)

12(46)

1.46

≤ 50 (Median)

161(88)

23(88)

Reference

> 50 (Median)

22(12)

3(12)

0.95

PTV prescription

Abbreviation: PTV planning target volume, PGTV planning gross tumor volume, V5/20 volume of lung receiving a dose ≥5/20 Gy, MLD mean lung dose
*By repeated analysis of variance test (ANOVA)
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SPSS, version 23.0 (IBM, Armonk, NY) and MedCalc,
version 14.8.1 (MedCalc Software bvba, Ostend, Belgium)
were used. Differences were considered significant if
P < 0.05 (2- sided).

Results
Patient’s characteristics

From January 2014 to October 2017, 183 consecutive
patients with follow-up lung toxicity data were evaluated.
Patients were treated with curative or palliative intent with
RT alone or combine with either surgery or chemotherapy.
The prescription dose was between 50 and 70 Gy. All of
these patients were only treated by IMRT technique.
Twenty six patients (14.2%) developed acute RP2 within 3
months after treatment. No patient suffered from grade 5
RP. Table 1 shows the clinical characteristics and their
correlation with the development of RP2. None of the
baseline clinical factors, including age, gender, smoking
history, clinical stage, PGTV or PTV volume, prescription
dose, chemo, surgery, BMI or target volume has statistical
significance with the risk of acute RP2.
Difference of lung dose from three lung volume
definitions

The mean dosimetric value comparison of V5, V20 and
MLD among the three lung volume contouring methods
are shown in Table 2. Repeated measures ANOVA shows
a significant difference between any 2-paired methods
(Ps = 0.000). The mean value difference for Lung-PTV
definition from the other two methods is relatively
large. The difference between Lung-PGTV and total
lung methods is small but significant.
Correlation of dosimetric factors with RP2

The difference of dose between acute RP2 patients
and non-RP2 patients are shown in Table 3. From the
Mann-Whitney U test, all dosimetric parameters from
Lung-PTV method have a significant difference between
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RP2 and non-RP2 patients (Ps < 0.05). For Lung-PGTV
method, only the V20 difference is significant (P = 0.046).
None of the parameters from Total Lung method shows a
significant difference between the two groups.
From logistic regression analysis, all of the dosimetric
factors from three methods are correlated with the incidence of RP2 (all Ps < 0.05). But each parameter from
Lung-PTV method shows a stronger correlation evidence
(smaller Ps) compared with the parameters from the other
two lung volume definitions (Table 4).
RP2 prediction evaluation

We used ROC curve analysis to evaluate dose parameters RP2 prediction ability. MLD from Lung-PTV
method has the highest AUC value of 0.647. Total lung
method parameters have the smallest AUC value among
the three methods. All AUC values of factors from
Lung-PTV are higher than Lung-PGTV method. Comparing with Lung-PGTV, according to Delong test [22],
Lung-PTV method has a significant AUC increase in V5
(P = 0.001) and MLD (P = 0.006). To limit RP incidence
less than 20% according to these NTCP models, the
MLD cutoff points are 12.5 Gy, 14.2 Gy, and 15.0 Gy for
Lung-PTV, Lung-PGTV, and Total Lung, respectively.
Comparing Lung-PTV and Lung-PGTV method, the
incidence probability has 54% difference (13% vs. 20%)
at MLD = 12.5 Gy, and 45% (20% vs. 29%) difference at
MLD = 14.2 Gy (Fig. 2).

Discussion
The current study found that different normal lung definitions could have a significant impact on V5, V20 and MLD
for IMRT treated lung cancer patients. This finding is in
line with the previous results from 3D-CRT [14, 15, 23],
indicating that the choice of lung definitions should not be
disregard in clinical IMRT practice. According to NTCP
models, Lung-PTV and Lung-PGTV methods could
have a 1.7 Gy MLD difference and up to 54% probability

Table 2 Difference of dosimetric factors among three lung definition methods
Factors
V5 (%)

V20 (%)

MLD (Gy)

P Value*

Mean Difference

95% CI

Lung-PTV vs. Lung-PGTV

2.2

2.0–2.4

< 0.001

Lung-PTV vs. Total Lung

2.7

2.5–3.0

< 0.001

Lung-PGTV vs. Total Lung

0.6

0.4–0.7

< 0.001

Lung-PTV vs. Lung-PGTV

3.5

3.3–3.8

< 0.001

Lung-PTV vs. Total Lung

4.5

4.2–4.8

< 0.001

Lung-PGTV vs. Total Lung

1.0

0.8–1.1

< 0.001

Lung-PTV vs. Lung-PGTV

1.7

1.6–1.8

< 0.001

Lung-PTV vs. Total Lung

2.3

2.1–2.4

< 0.001

Lung-PGTV vs. Total Lung

0.6

0.5–0.7

< 0.001

Abbreviation: PTV planning target volume, PGTV planning gross tumor volume, V5/20 volume of lung receiving a dose ≥5/20 Gy, MLD mean lung dose
*By repeated analysis of variance test (ANOVA)
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Table 3 Difference of dosimetric factors between RP2 and nonRP2 groups
Factors

P Value*

Non-RP2

RP2

Median Range

Median Range

V5 Lung-PTV (%)

48

23–76

50.5

V20 Lung-PTV (%)

18

8–26

19

MLD Lung-PTV (Gy)

10.3

6.0–15.1 11.3

V5 Lung-PGTV (%)

51

26–76

52.5

33–80

0.085

V20 Lung-PGTV (%)

22

11–31

24

Lung-PTV method
31–78

0.046

15–31

0.035

7.9–15.6

0.016

Lung-PGTV method

MLD Lung-PGTV (Gy) 12.1

18–34

0.046

7.0–17.0 13.1

9.7–18.1

0.076

Total Lung Method
V5 Total Lung (%)

52

27–77

53

36–80

0.091

V20 Total Lung (%)

23

11–31

24

20–36

0.080

MLD Total Lung (Gy) 12.6

7.2–17.3 13.7

10.1–19.6 0.097

Abbreviation: RP2 radiation pneumonitis≥ grade 2, PTV planning target volume,
PGTV planning gross tumor volume, V5/20 volume of lung receiving a dose
≥5/20 Gy, MLD mean lung dose
*By Mann-Whitney U test

disagreement when limiting RP2 incidence under 20%.
We also found that dosimetric parameters, not clinical
variables, are significantly correlated with RP2 development. All V5, V20, and MLD from Lung-PTV definition
show stronger evidence in the correlation with RP2 development than the other two definitions. It is interesting to
note that V5 and MLD from Lung-PTV definition could
significantly improve the RP2 prediction performance
compared with those from Lung-PGTV method based on
our ROC curves analysis.
To our knowledge, this is the first study to demonstrate the impact of different lung volume definitions on
dosimetric parameters on IMRT treated lung cancer
patients. We further analyze which lung defined method
Table 4 Univariate analysis of dosimetric factors related to the
occurrence of grade ≥ 2 acute radiation pneumonitis
Factors

Odds Ratio

95% CI

P Value*

V5 Lung-PTV

1.054

1.014–1.096

0.008

V5 Lung-PGTV

1.048

1.007–1.091

0.023

V5 Total Lung

1.049

1.007–1.094

0.022

V20 Lung-PTV

1.204

1.059–1.369

0.005

V20 Lung-PGTV

1.164

1.039–1.305

0.009

V20 Total Lung

1.137

1.015–1.272

0.026

MLD Lung-PTV

1.421

1.116–1.809

0.004

MLD Lung-PGTV

1.271

1.038–1.557

0.021

MLD Total Lung

1.232

1.012–1.501

0.038

Abbreviation: CI confidence interval, PTV planning target volume, PGTV
planning gross tumor volume, V5/20 volume of lung receiving a dose ≥5/20
Gy, MLD mean lung dose
*By univariate logistic regression analysis

has a better performance in RP2 correlation and prediction.
The magnitudes of the dose differences from our results
could have a significant clinical impact. In the Quantitative
Analysis of Normal Tissue Effects in Clinic (QUANTEC)
lung project, over 70 published articles were reviewed but
dosimetric data were calculated from inconsistent lung
volume definitions [6]. The dose-RP2 relationship disparity
from various studies could be reduced by overcoming the
incompatible lung volume define methods. A meta-analysis
by Palma et al. used a linear imputation equation to the
convert V20 and MLD between Lung-PTV and LungPGTV [24]. In this way, they could convert data from
either a method or another. However, from our experience,
the PTV is exceedingly different from a patient to another.
A simple fit equation could not accurately convert dosimetric parameters between two methods for a specific
patient, especially with a PTV size far from the mean
value.
Wang et al. showed that the lung-PGTV method
seems to provide more accurate lung toxicity prediction
[14] than the Lung-PTV method. Several reasons may
cause this opposite finding to our result: First, the CTV
defined in their RP2 prediction results was contoured with
a 0.8 cm uniform expansion directly from GTV instead of
the CTV including involved lymph node regions contoured
by a physician in our study. Excluding an expanded GTV
and excluding clinical prescribed PTV are two inherently
distinguished methods, which will provide different calculated DVHs. Second, we included stage IV palliative
radiation therapy patients in our study, the treatment
prescription has a broader dose spectrum. Third, we
included the postoperative patients, which don’t have a
PGTV. The only treatment targets in these cases are
the PTVs. Furthermore, all of our treatment were using
IMRT instead of 3DCRT, the nonstandard dose distribution might contribute to this opposite result.
Treatment plans usually have a goal of delivering a
prescribed dose to at least 95% of the PTV for both
3D-CRT and IMRT techniques. Admittedly, the dose
heterogeneity index within the PTV could be diverse for
these two techniques [25], the PTV dose coverage is
always around 95%. The main dose distribution difference
between these two techniques is located in the region outside the treatment target volume, as IMRT tends to deliver
a higher conformable dose at the expense of irradiating
larger lung volume. A specific lung cancer patient plan
using IMRT could have similar V20 and MLD compared
with using 3D-CRT while having two entirely different
shapes of DVHs. These different histogram shapes primarily come from the dose distribution disparity outside PTV,
and it is very likely contributing to various lung toxicity
outcome.
We recognized that this study is limited in several aspects.
First, treatment plans were calculated in two different
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Fig. 2 a Receiver operating curves for mean lung dose (MLD) associated with the grade ≥ 2 radiation pneumonitis from three normal lung
definitions. b The mean lung dose and the grade ≥ 2 radiation pneumonitis relationship models from three normal lung definitions

treatment planning systems. The dose-volume histogram
parameters could be marginally different if a patient’s dose
was calculated using another algorithm. Second, it was a single institution retrospective study, 183 IMRT treated patients were relatively a small sample size, considering there
were only 26 acute RP2 patients. Nevertheless, this study
validated the non-negligible impact of different lung definitions on dose and RP2 prediction using IMRT technique.
Technique similarity and normal lung definitions should be
taken into consideration before using specific dose constraints in clinical practice and decision making. We identified dosimetric parameters from Lung-PTV method
provide stronger evidence in the correlation of RP2, and
better RP2 prediction performance.

Conclusions
The same dose constraint from three normal lung definitions could predict significant different RP2 rate. The
Lung-PTV method may be better than or at least as
good as Lung-PGTV method regarding RP2 prediction.
We recommend adding dose constraints from Lung-PTV
method in clinical treatment plan evaluation. Since the
dose distribution differences among multiple techniques
mainly locate in the lung region outside PTV, dosimetric
data from Lung-PTV method could help us further
study the more precise lung dose constraints for currently
common techniques like IMRT.
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3D-CRT: Three-dimensional Conformal Radiation Therapy; ANOVA: The
Analysis of Variance; AUC: Area Under the Receiver Operating Characteristic
Curve; BMI: Body Mass Index; CI: Confidential Interval; CTCAE: Common
Terminology Criteria for Adverse Events; CTV: Clinical Target Volume;
DVH: Dose-volume Histogram; IMRT: Intensity Modulated Radiation Therapy
(IMRT); Lung-PGTV: Excluding PGTV from Bilateral Lung; Lung-PTV: Excluding

PTV from Bilateral Lung; MLD: Mean Lung Dose; NTCP: Normal Tissue
Complication Probability; PTV: Planning Target Volume; ROC: Receiver
Operating Characteristic; RP: Radiation Pneumonitis; RP2: Grade 2 or Higher
RP; TD50: Toxicity Occurs in 50% of the Population; V5/20: The Percentage of
Lung Volume Receiving Equal to or Greater than 5 or 20 Gy;
VMAT: Volumetric Modulated Arc Therapy
Acknowledgements
The authors gratefully acknowledge Dr. Feng-Ming (Spring) Kong, from Case
Western Reserve University, for the help with the abstract and valuable support
for this study.
Funding
This work was funded by the National Natural Science Foundation of China
(81874221), Zhejiang Provincial Medicine and Health Foundation
(2015KYA240), and Taizhou Science and Technology Bureau (15yw01 and
1802ky07).
Availability of data and materials
The datasets are available to all interested researchers on reasonable request
from corresponding author.
Authors’ contributions
HY, WL, and YM had the ideas and participated in the design of the study;
WW, HY and YM carried out the statistical analysis; YN, YS and XT analyzed
and correlated the dosimetry data with radiation pneumonitis; CJ and HY
analyzed the patient radiation pneumonitis following radiotherapy; YM and
HY were major contributors to the writing of the manuscript. All authors
read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by our institutional review board, and the informed
consent requirement was waived because the retrospective design.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

Meng et al. Radiation Oncology

(2019) 14:7

Author details
1
Laboratory of Cellular and Molecular Radiation Oncology, Radiation
Oncology Institute of Enze Medical Health Academy, Taizhou 317000,
Zhejiang Province, China. 2Department of Radiation Oncology, Affiliated
Taizhou hospital of Wenzhou Medical University, Taizhou 317000, Zhejiang
Province, China. 3Department of Radiation Medicine, University of Kentucky,
Lexington, KY 40536, USA.

Page 8 of 8

19.

20.
21.

Received: 18 October 2018 Accepted: 17 December 2018
22.
References
1. Hernando ML, Marks LB, Bentel GC, Zhou SM, Hollis D, Das SK, et al.
Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in
201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):650–9.
2. Marks L, Yu X, Vujaskovic Z, Smalljr W, Folz R, Anscher M. Radiation-induced
lung injury. Semin Radiat Oncol. 2003;13(3):333–45.
3. Rodrigues G, Lock M, D'Souza D, Yu E, Van Dyk J. Prediction of radiation
pneumonitis by dose - volume histogram parameters in lung cancer--a
systematic review. Radiother Oncol. 2004;71(2):127–38.
4. Kong F-M, Hayman JA, Griffith KA, Kalemkerian GP, Arenberg D, Lyons S, et
al. Final toxicity results of a radiation-dose escalation study in patients with
non–small-cell lung cancer (NSCLC): predictors for radiation pneumonitis
and fibrosis. Int J Radiat Oncol Biol Phys. 2006;65(4):1075–86.
5. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, et al.
Clinical dose–volume histogram analysis for pneumonitis after 3D treatment
for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;
45(2):323–9.
6. Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, et al.
Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys.
2010;76(3 Suppl):S70–6.
7. Miller KL, Shafman TD, Anscher MS, Zhou SM, Clough RW, Garst JL, et al.
Bronchial stenosis: an underreported complication of high-dose external beam
radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys. 2005;61(1):64–9.
8. Yamashita H, Nakagawa K, Nakamura N, Koyanagi H, Tago M, Igaki H, et al.
Exceptionally high incidence of symptomatic grade 2-5 radiation
pneumonitis after stereotactic radiation therapy for lung tumors. Radiat
Oncol. 2007;2:21.
9. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use
in the US, 2004. Cancer: interdisciplinary international journal of the. Am
Cancer Soc. 2005;104(6):1296–303.
10. Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, et al.
Influence of technologic advances on outcomes in patients with unresectable,
locally advanced non–small-cell lung cancer receiving concomitant
chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(3):775–81.
11. Harris JP, Murphy JD, Hanlon AL, Le QT, Loo BW Jr, Diehn M. A population-based
comparative effectiveness study of radiation therapy techniques in stage III
non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;88(4):872–84.
12. National Comprehensive Cancer Network. Non-small cell lung Cancer.
Version 4, 2018. [cited 2018 March 13]; Available at http://www.nccn.org.
13. Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact
of intensity-modulated radiation therapy technique for locally advanced
non-small-cell lung Cancer: a secondary analysis of the NRG oncology RTOG
0617 randomized clinical trial. J Clin Oncol. 2017;35(1):56–62.
14. Wang W, Xu Y, Schipper M, Matuszak MM, Ritter T, Cao Y, et al. Effect of
normal lung definition on lung dosimetry and lung toxicity prediction in
radiation therapy treatment planning. Int J Radiat Oncol Biol Phys. 2013;
86(5):956–63.
15. Kabolizadeh P, Kalash R, Huq M, Greenberger J, Heron D, Beriwal S.
Dosimetric definitions of total lung volumes in calculating parameters predictive
for radiation-induced pneumonitis. Am J Clin Oncol. 2015;38(4):401–4.
16. Jenkins P, Watts J. An improved model for predicting radiation pneumonitis
incorporating clinical and dosimetric variables. Int J Radiat Oncol Biol Phys.
2011;80(4):1023–9.
17. De Ruysscher D, Wanders S, Minken A, Lumens A, Schiffelers J, Stultiens C,
et al. Effects of radiotherapy planning with a dedicated combined PET-CTsimulator of patients with non-small cell lung cancer on dose limiting
normal tissues and radiation dose-escalation: a planning study. Radiother
Oncol. 2005;77(1):5–10.
18. Kong FM, Ritter T, Quint DJ, Senan S, Gaspar LE, Komaki RU, et al.
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas

23.

24.

25.

for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial
plexus. Int J Radiat Oncol Biol Phys. 2011;81(5):1442–57.
Nestle U, De RD, Ricardi U, Geets X, Belderbos J, Pöttgen C, et al. ESTRO
ACROP guidelines for target volume definition in the treatment of locally
advanced non-small cell lung cancer. Radiother Oncol. 2018;127(1):1–5.
Health UDo, Services H. National Cancer Institute. Common Terminology
Criteria for Adverse Events (CTCAE) Version 4.03, 2010. 2016.
Semenenko V, Li X. Lyman-Kutcher-Burman NTCP model parameters for
radiation pneumonitis and xerostomia based on combined analysis of
published clinical data. Phys Med Biol. 2008;53(3):737–55.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under
two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics. 1988;44(3):837–45.
Biau J, Bellière A, Verrelle P, Lapeyre M. Excluding either gross tumor
volume or planning target volume from the normal lung volume in lung
cancer irradiation: evaluation of the dosimetric impact. Pract Radiat Oncol.
2013;3(2):e79–85.
Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al.
Predicting radiation pneumonitis after chemoradiation therapy for lung
cancer: an international individual patient data meta-analysis. Int J Radiat
Oncol Biol Phys. 2013;85(2):444–50.
Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, et al. Dose and
volume reduction for normal lung using intensity-modulated radiotherapy
for advanced-stage non–small-cell lung cancer. Int J Radiat Oncol Biol Phys.
2004;58(4):1258–67.

